Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Psychosis During Pregnancy: Treatment Considerations

Psychosis During Pregnancy: Treatment Considerations The onset of psychosis during pregnancy presents several difficult management decisions and a careful risk–benefit analysis is required. Withholding antipsychotic treatment may produce more risks than benefits. Studies on neuroleptic teratogenicity are contradictory. Most of the commonly used neuroleptics exhibit a pregnancy risk of category C. Neuroleptic use during pregnancy may be associated with adverse effects in the pre- and postnatal period. These concerns include compromising uterine blood flow, post-partum neonatal sedation, and extrapyramidal signs expressed in the neonate. Each neuroleptic exhibits a unique pharmacokinetic profile. The antipsychotic properties and side effects considered most significant include sedation, half-life, hypotension, and apparent hydrophilicity. In this case study a decision to select molindone was based on these parameters. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Psychosis During Pregnancy: Treatment Considerations

Pinkofsky, Harold
Annals of Clinical Psychiatry , Volume 9 (3) – Sep 18, 2004
Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/psychosis-during-pregnancy-treatment-considerations-hE6n18RWYg
Publisher
Springer Journals
Copyright
Copyright © 1997 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1026234125565
Publisher site
See Article on Publisher Site

Abstract

The onset of psychosis during pregnancy presents several difficult management decisions and a careful risk–benefit analysis is required. Withholding antipsychotic treatment may produce more risks than benefits. Studies on neuroleptic teratogenicity are contradictory. Most of the commonly used neuroleptics exhibit a pregnancy risk of category C. Neuroleptic use during pregnancy may be associated with adverse effects in the pre- and postnatal period. These concerns include compromising uterine blood flow, post-partum neonatal sedation, and extrapyramidal signs expressed in the neonate. Each neuroleptic exhibits a unique pharmacokinetic profile. The antipsychotic properties and side effects considered most significant include sedation, half-life, hypotension, and apparent hydrophilicity. In this case study a decision to select molindone was based on these parameters.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 18, 2004

References

  • Symptomatology of affective and psychotic illnesses related to childbearing
    Wisner, KL; Peindl, K; Hanusa, BH
  • An overview of somatic treatment of psychosis during pregnancy and postpartum
    Nurnberg, HG
  • The use of psychotropic agents in pregnancy and lactation
    Mortola, JF
  • Antipsychotic drug use and birth defects: An epidemologic reassessment
    Edlund, MJ; Craig, TJ
  • Limb malformation following maternal use of haloperidol
    Kopelman, AE; McCullar, FW; Heggeness, L
  • Haloperidol and limb deformity
    Hanson, JW; Oakley, GP
  • Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum
    Wan Waes, A; Van De Velde, E
  • Neuroleptiques, schizophrene et grosesse
    Godet, PF; Marie-Cardine, M
  • Congenital malformations with psychopharmacologic agents
    Anath, J
  • Trifluoperazine and pregnancy
    Moriarty, AJ; Nance, MR
  • Possible teratogenic effects of phenothiazine in human beings
    Rumeau-Rouquette, C; Goujard, J; Huel, G
  • An evaluation of the teratogenicity of certain antinauseant drugs
    Milkovich, L; Van Den Berg, BJ
  • Fetal damage due to ECT, insulin, coma, chlorpromazine, or reserpine
    Sobel, DE
  • Pregnancy and delivery complications in the births of an unselected series of Finnish children with schizophrenic mothers
    Wrede, G; Mednick, SA; Huttunen, MO; Nilsson, CG
  • Maternal psychotropic medications and neonatal behavior
    Auerbach, JG; Hans, SL; Marcus, J; Maeir, S
  • Extrapyramidal dysfunction in an infant of a schizophrenic mother
    Hill, RM; Desmond, MM; Kay, JL
  • Phenothiazine-induced extrapyramidal dysfunction in the neonate
    Tamer, A; McKey, R; Arias, D; Worley, L; Fogel, BJ
  • Small left colon syndrome associated with maternal ingestion of psychotropic drugs
    Falterman, CG; Richardson, CJ
  • Infant jaundice after phenothiazines
    Scokel, P; Jones, WN
  • Children of mothers maintained on pharmacotherapy during pregnancy and postpartum
    Kris, E
  • Children born to mothers treated with chlorpromazine during pregnancy
    Ayd, FJ
  • The Practitioner's Guide to Psychoactive Drugs
    Gelenberg, AJ
  • Antischizophrenic drugs: differential plasma binding and therapeutic activity
    Freedberg, KA; Innis, RB; Creese, I; Snyder, SH
  • Goodman and Gillman's the Pharmacologic Basis of Therapeutics
    Baldessarini, RG
  • Drugs in Pregnancy and Lactation
    Briggs, GG; Freeman, RK; Yaffe, SJ
  • Reviews in Perinatal Medicine
    Nahas, G; Gougard, J
  • Williams Obstetrics
    Cunningham, FG; MacDonald, PC; Gant, NF; Leveno, KJ; Gilstrap, LC
  • Neuroleptic induced seizures. An in vitro technique for assessing relative risk
    Oliver, AP; Luchins, DJ; Wyatt, RJ
  • Weight reduction in schizophrenics by molindone
    Gardos, G; Cole, JO
  • Effect of molindone on weight change in hospitalized schizophrenic patients
    Parent, MM; Roy, S; Sramek, J; Lawson, W; Herrera, J
  • Neuroleptic affinities for human brain receptor and their use in predicting adverse effects
    Richelson, ER
  • Pharmacology of neuroleptics in use in the United States
    Richelson, ER
  • A Pocket Reference for Psychiatrists
    Jenkins, SC; Hansen, MR
  • Rational Psychophamacotherapy and the Right to Treatment
    Ayd, FJ
  • Principles and Practice of Psychopharmacotherapy
    Janicak, PG; Davis, JM; Preskorn, SH; Ayd, FJ
  • Continuous versus targeted medication in schizophrenic outpatients: outcomes results
    Carpenter, WT; Hanlon, TE; Heinrichs, DW
  • Presistence of haloperidol in the brain
    Cohen, BM; Babb, S; Campbell, A; Baldessarini, RJ
  • Psychologic and clinical effects of chlopromazine and their relationship to plasma level
    Sakalis, G; Curry, SH; Mould, GP; Lader, MH
  • Clozapine
    Jann, MW